CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Non-controlling Interest
Shares, Issued at Dec. 31, 2018		136,512,522
Stockholders' Equity Attributable to Parent at Dec. 31, 2018	$ 729,779	$ 1,365	$ (2,103)	$ (98,030)	$ 828,547
Other Noncontrolling Interests at Dec. 31, 2018						$ 0
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		764,785
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	0	$ (8)		(8)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	1,169			1,169
Stock Repurchased During Period, Shares		(13,460,164)
Treasury Stock, Retired, Par Value Method, Amount		$ (135)
Treasury Stock, Value, Acquired, Cost Method			613
Treasury Stock, Retired, Cost Method, Amount					(44,831)
Noncontrolling Interest, Period Increase (Decrease)	572					572
Stock Repurchased and Retired During Period, Value	(44,353)
Net Income (Loss) Attributable to Parent					6,680
Net Income (Loss) Attributable to Noncontrolling Interest						(63)
Net (loss) income	6,617
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	6,617
Shares, Issued at Mar. 31, 2019		123,817,143
Stockholders' Equity Attributable to Parent at Mar. 31, 2019	693,784	$ 1,238	(1,490)	(96,869)	790,396
Other Noncontrolling Interests at Mar. 31, 2019						509
Shares, Issued at Dec. 31, 2018		136,512,522
Stockholders' Equity Attributable to Parent at Dec. 31, 2018	729,779	$ 1,365	(2,103)	(98,030)	828,547
Other Noncontrolling Interests at Dec. 31, 2018						0
Noncash liquidating distribution (0.11591985 shares of Evofem Biosciences, Inc. common stock distributed per share of the Company’s common stock )	0
Net Income (Loss) Attributable to Parent	(15,523)
Net Income (Loss) Attributable to Noncontrolling Interest	(340)
Net (loss) income	(15,863)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	(15,863)
Shares, Issued at Sep. 30, 2019		114,184,610
Stockholders' Equity Attributable to Parent at Sep. 30, 2019		$ 1,142	0	(100,419)	736,695
Other Noncontrolling Interests at Sep. 30, 2019						16
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Sep. 30, 2019	637,434
Shares, Issued at Mar. 31, 2019		123,817,143
Stockholders' Equity Attributable to Parent at Mar. 31, 2019	693,784	$ 1,238	(1,490)	(96,869)	790,396
Other Noncontrolling Interests at Mar. 31, 2019						509
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		37,996
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	0
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	2,175			2,175
Stock Repurchased During Period, Shares		(8,185,970)
Treasury Stock, Retired, Par Value Method, Amount		$ (81)
Treasury Stock, Value, Acquired, Cost Method			944
Treasury Stock, Retired, Cost Method, Amount					(26,897)
Noncontrolling Interest, Period Increase (Decrease)	13			229		(216)
Stock Repurchased and Retired During Period, Value	(26,034)
Net Income (Loss) Attributable to Parent					(4,419)
Net Income (Loss) Attributable to Noncontrolling Interest						(95)
Net (loss) income	(4,514)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	(4,514)
Shares, Issued at Jun. 30, 2019		115,669,169
Stockholders' Equity Attributable to Parent at Jun. 30, 2019		$ 1,157	(546)	(94,465)	759,080
Other Noncontrolling Interests at Jun. 30, 2019						198
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Jun. 30, 2019	665,424
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		(18,061)
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	(8)				(8)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	2,059			2,059
Stock Repurchased During Period, Shares		(1,466,498)
Treasury Stock, Retired, Par Value Method, Amount		$ (15)
Treasury Stock, Value, Acquired, Cost Method			546
Treasury Stock, Retired, Cost Method, Amount					(4,609)
Stock Repurchased and Retired During Period, Value	(4,078)
Exchange of debt	(8,013)			(8,013)
Net Income (Loss) Attributable to Parent	(17,784)				(17,784)
Net Income (Loss) Attributable to Noncontrolling Interest	(182)					(182)
Net (loss) income	(17,966)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	(17,966)
Shares, Issued at Sep. 30, 2019		114,184,610
Stockholders' Equity Attributable to Parent at Sep. 30, 2019		$ 1,142	0	(100,419)	736,695
Other Noncontrolling Interests at Sep. 30, 2019						16
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Sep. 30, 2019	637,434
Shares, Issued at Dec. 31, 2019		124,302,616
Stockholders' Equity Attributable to Parent at Dec. 31, 2019	593,200	$ 1,243	0	(78,875)	670,832
Other Noncontrolling Interests at Dec. 31, 2019	78					78
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2019	593,278
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		1,781,197
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	0	$ (18)		(18)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	14,453			14,453
Stock Repurchased During Period, Shares		(5,564,841)
Treasury Stock, Retired, Par Value Method, Amount		$ (56)
Treasury Stock, Value, Acquired, Cost Method			(2,244)		(17,978)
Noncontrolling Interest, Period Increase (Decrease)						100
Stock Repurchased and Retired During Period, Value	(20,278)
Adjustments to Additional Paid in Capital, Other				683
Noncontrolling Interest, Increase from Subsidiary Equity Issuance	783
Write off of Deferred Debt Issuance Cost	(3,911)			(3,911)
Call option unwind	801			801
Net Income (Loss) Attributable to Parent					(31,723)
Net Income (Loss) Attributable to Noncontrolling Interest						(288)
Net (loss) income	(32,011)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	(32,011)
Shares, Issued at Mar. 31, 2020		120,518,972
Stockholders' Equity Attributable to Parent at Mar. 31, 2020		$ 1,205	(2,244)	(66,867)	621,131
Other Noncontrolling Interests at Mar. 31, 2020						(110)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Mar. 31, 2020	553,115
Shares, Issued at Dec. 31, 2019		124,302,616
Stockholders' Equity Attributable to Parent at Dec. 31, 2019	593,200	$ 1,243	0	(78,875)	670,832
Other Noncontrolling Interests at Dec. 31, 2019	78					78
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Dec. 31, 2019	593,278
Noncash liquidating distribution (0.11591985 shares of Evofem Biosciences, Inc. common stock distributed per share of the Company’s common stock )	(64,400)
Net Income (Loss) Attributable to Parent	(77,296)
Net Income (Loss) Attributable to Noncontrolling Interest	(659)
Net (loss) income	(77,955)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	(77,955)
Shares, Issued at Aug. 31, 2020		114,111,358
Stockholders' Equity Attributable to Parent at Aug. 31, 2020	425,214	$ 1,141	0	(65,337)	489,891
Other Noncontrolling Interests at Aug. 31, 2020						(481)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Aug. 31, 2020	425,214
Shares, Issued at Mar. 31, 2020		120,518,972
Stockholders' Equity Attributable to Parent at Mar. 31, 2020		$ 1,205	(2,244)	(66,867)	621,131
Other Noncontrolling Interests at Mar. 31, 2020						(110)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Mar. 31, 2020	553,115
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		183,903
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	460	$ (2)		458
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	245			245
Stock Repurchased During Period, Shares		(6,758,147)
Treasury Stock, Retired, Par Value Method, Amount		$ (68)
Treasury Stock, Value, Acquired, Cost Method			2,244
Treasury Stock, Retired, Cost Method, Amount					(21,267)
Stock Repurchased and Retired During Period, Value	(19,091)
Noncash liquidating distribution (0.11591985 shares of Evofem Biosciences, Inc. common stock distributed per share of the Company’s common stock )	(64,400)				(64,400)
Net Income (Loss) Attributable to Parent					(49,971)
Net Income (Loss) Attributable to Noncontrolling Interest						(357)
Net (loss) income	(50,328)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	(50,328)
Shares, Issued at Jun. 30, 2020		113,944,728
Stockholders' Equity Attributable to Parent at Jun. 30, 2020		$ 1,139	0	(66,164)	485,493
Other Noncontrolling Interests at Jun. 30, 2020						(467)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Jun. 30, 2020	420,001
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture		166,630
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture	0	$ (2)		(2)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	829			829
Net Income (Loss) Attributable to Parent	4,398				4,398
Net Income (Loss) Attributable to Noncontrolling Interest	(14)					(14)
Net (loss) income	4,384
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	4,384
Shares, Issued at Aug. 31, 2020		114,111,358
Stockholders' Equity Attributable to Parent at Aug. 31, 2020	425,214	$ 1,141	$ 0	$ (65,337)	$ 489,891
Other Noncontrolling Interests at Aug. 31, 2020						$ (481)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest at Aug. 31, 2020	$ 425,214